Teva Identifies Teriparatide Importance Amid US Launch Drought
Israeli Firm Sees 15% North America Gx Sales Decline In Q1
Executive Summary
Teva acknowledged that it was “not independent of the macro environment in the US,” as it saw another significant drop off for its North America generics business amid a lack of new launches. The Israeli giant took the unusual step of singling out a complex generic asset – its proposed generic to Eli Lilly’s Forteo – as “the most important” potential launch for its 2022 top line.